Myasthenia gravis（MG） is an autoimmune disease caused by specific autoantibodies at the neuromuscular junction. The traditional immunotherapy drugs for MG include glucocorticoids，immunosuppressants，and intravenous immunoglobulins. Although these immunosuppressants are effective for most MG patients，the adverse reactions or complications brought by these drugs remain a challenge in MG treatment. In addition，non-specific immunosuppressants often take effect slowly and carry the risk of bone marrow suppression，increased infection，and tumor development. With the emergence of various new targeted biological agents，the treatment of MG has entered the era of molecular immunity，providing patients and clinicians with more treatment options. This article reviews three types of novel biological agents that act on different targets in the pathophysiological process of MG，including B-cell depleting agents，terminal complement C5 inhibitors，and neonatal Fc receptor inhibitors. Compared with traditional immunosuppressants，these targeted drugs have fewer side effects，take effect faster，and have the potential ability for sustained and long-term remission in MG.